| Title |
Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study
|
|---|---|
| Published in |
BMC Neurology, May 2017
|
| DOI | 10.1186/s12883-017-0869-3 |
| Pubmed ID | |
| Authors |
Michail Vikelis, Emmanouil V. Dermitzakis, Konstantinos C. Spingos, Georgios G. Vasiliadis, George S. Vlachos, Evaggelia Kararizou |
| Abstract |
Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis. A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment. A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3 months (p < 0.001 for all of the three changes). Twenty-three patients (65.7%) expressed their satisfaction and intent to continue treatment with Cefaly®. Compliance was higher among satisfied subjects compared to non-satisfied subjects. None of the explored factors were significantly associated with the reason for the failure of topiramate. Three-months of preventive treatment for episodic or chronic migraine with t-SNS proved to be an effective, safe and well tolerated option for the treatment of patients with migraine who were intolerant or did not respond to topiramate. ClinicalTrials NCT03125525 . Registered 21 April 2017. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 50% |
| Costa Rica | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 76 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 13% |
| Other | 7 | 9% |
| Student > Postgraduate | 6 | 8% |
| Student > Ph. D. Student | 5 | 6% |
| Researcher | 5 | 6% |
| Other | 13 | 17% |
| Unknown | 31 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 27% |
| Neuroscience | 7 | 9% |
| Nursing and Health Professions | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 34 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 436. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2021.
All research outputs
#56,929
of 23,660,680 outputs
Outputs from BMC Neurology
#4
of 2,525 outputs
Outputs of similar age
#1,373
of 314,685 outputs
Outputs of similar age from BMC Neurology
#1
of 50 outputs
Altmetric has tracked 23,660,680 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,525 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,685 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.